Literature DB >> 1314286

Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure.

T Nowak1, J P Gregersen, U Klockmann, L B Cummins, J Hilfenhaus.   

Abstract

Human immunoglobulins are plasma derivatives with a low risk of transmitting viral infections. To the present, no proven case of human immunoglobulins transmitting human immunodeficiency viruses has been reported. However, there have been a few reports on the transmission of hepatitis C virus by these plasma proteins. To improve further the safety of both 5s iv human immunoglobulins and 7s im immunoglobulins, we introduced a 10-hour heat treatment of the aqueous solutions at 60 degrees C (i.e., pasteurization) into the manufacturing procedure. This treatment was not added to the manufacturing procedure of 7s iv immunoglobulin that already contained the S-sulfonation as a virus inactivating method. We now report on experimental data that show that the whole manufacturing procedures of the above immunoglobulins inactivate efficiently hepatitis C virus and that the specific virus inactivation methods alone, namely, pasteurization or S-sulfonation, also inactivate completely viruses of the flavivirus family, to which the hepatitis C virus belongs. The inactivation of the Flaviviridae bovine viral diarrhea virus, tick-borne encephalitis virus, and yellow fever virus by pasteurization or S-sulfonation was at least 10(5). The clearance of HCV achieved by the entire manufacturing process of each of these immunoglobulins was also at least 10(5). The experiments therefore show that pasteurization or S-sulfonation provides a high margin of safety to human immunoglobulins regarding the transmission of hepatitis C virus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314286     DOI: 10.1002/jmv.1890360311

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

Review 1.  Criteria for the appropriate drug utilisation of immunoglobulin.

Authors:  P Thürmann; S Harder
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

Review 2.  Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

Authors:  H B Slade
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

3.  A prospective controlled crossover trial of a new heat-treated intravenous immunoglobulin.

Authors:  S R Zuhrie; A D Webster; R Davies; A C Fay; T B Wallington
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

Review 4.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

5.  Effective inactivation of a wide range of viruses by pasteurization.

Authors:  Albrecht Gröner; Connie Broumis; Randel Fang; Thomas Nowak; Birgit Popp; Wolfram Schäfer; Nathan J Roth
Journal:  Transfusion       Date:  2017-11-16       Impact factor: 3.157

6.  Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process.

Authors:  C P Caricati; L Oliveira-Nascimento; J T Yoshida; A T P Caricati; I Raw; M A Stephano
Journal:  Biotechnol Prog       Date:  2013-06-27

7.  Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.

Authors:  K M Remington; S R Trejo; G Buczynski; H Li; W P Osheroff; J P Brown; H Renfrow; R Reynolds; D Y Pifat
Journal:  Vox Sang       Date:  2004-07       Impact factor: 2.144

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.